Formycon AG
FYB.DESDAX
19,18 €
Dividend yield—
Continuity—
Dividend—
DiviScore
High RiskPerformance6/35
Dividend Quality0/35
AGM Date
—Ex-Date
—Payment
—CAGR 3Y
-33.9%CAGR 5Y
-19.7%CAGR 10Y
+0.5%€10,000 invested in 2016 · with dividend reinvestment
End Value
10.508,71 €
Total Return
+5.1%
Annual Return
0.5% p.a.
Dividends Received
0,00 €
This company does not pay dividends
This company reinvests profits fully into growth and innovation. Investors benefit exclusively from share price appreciation.
View dividend-paying stocksAbout Formycon AG
Formycon, based near Munich, develops biosimilars, lower-cost copies of expensive biological medicines, taking them from development through approval and partnering to bring them to market. Its pipeline targets big-selling drugs in areas such as eye disease and immunology as their patents expire. Formycon pays no dividend, channelling its resources into developing and launching biosimilars, which leaves its score at the bottom. This is a biotech growth stock for investors betting on the expanding biosimilars market, not a source of income.
Frequently Asked Questions
The next payment date is not yet announced.
Formycon AG has a DiviScore of 12/100. DiviScore rates dividend stocks based on price performance, dividend quality, fundamentals, and stability.
Formycon AG currently pays no dividend or data is not yet available.
Formycon AG (FYB.DE) is a member of SDAX. Current data including price, dividend, and DiviScore is updated daily.
DiviScore is a proprietary 100-point rating based on four pillars: Performance (35 pts), Dividend Quality (35 pts), Fundamentals (15 pts), and Stability (15 pts). It simulates a 10-year investment with automatic dividend reinvestment.